Tokai Pharmaceuticals, Inc. Company Profile
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, galeterone (TOK-001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic. Privately held Tokai is based in Cambridge, Massachusetts and is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visit www.tokaipharma.com.
News Articles
Tokai Pharmaceuticals in Series E financing deal for $35.5 million
Tokai announced that the pharmaceutical company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone, Tokai’s lead prostate cancer...
Tokai Pharmaceuticals raises $35.5M in Series E financing
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based o...
Tokai Looks to Follow Fast Behind J&J, Medivation in Prostate Cancer
Johnson & Johnson (NYSE: JNJ) and Medivation (NASDAQ: MDVN) shook up the prostate cancer world the past couple years by introducing two important new FDA-approved treatments. Now Cambridge, MA-bas...
Tokai raises $35.5 million in E round
Tokai Pharmaceuticals Inc. (Cambridge, Mass.) raised $35.5 million in a series E round from existing investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors. T...
Series E round brings $35.5mm to [Tokai]
[Tokai Pharmaceuticals Inc.] (prostate cancer therapeutics) raised $35.5mm through its Series E round from returning backers Apple Tree Partners and Novartis Venture Funds, along with 17 other investo...
Tokai Pharmaceuticals Announces Appointment of Jodie Morrison as Chief Executive Officer
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the appointment of Jodie Morrison to the...
Tokai completes venture financing
Tokai Pharmaceuticals to Participate in Upcoming Investment Conferences
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that Martin D. Williams, president and ch...
Drugs and Medications
None
PubMed Articles
Tokai University Hospital has been operating a magnetic resonance/x-ray/operating suite (MRXO) since 2006. Developed with the support of Philips Healthcare, the MRXO is an operating suite equipped wit...
Clinical Trials
None
Companies
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, galeterone (TOK-001), i...
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, TOK-001, is the first i...
More Information about "Tokai Pharmaceuticals, Inc." on BioPortfolio
We have published hundreds of Tokai Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Tokai Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Tokai Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tokai Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Tokai Pharmaceuticals, Inc. Drugs and Medications on this site too.
